Fluconazole analogues with metal-binding motifs impact metal-dependent processes and demonstrate antifungal activity in Candida albicans.

Published

Journal Article

Azole antifungals are an important class of antifungal drugs due to their low cost, ability to be administered orally, and broad-spectrum activity. However, their widespread and long-term use have given rise to adaptation mechanisms that render these compounds less effective against common fungal pathogens, including Candida albicans. New antifungals are desperately needed as drug-resistant strains become more prevalent. We recently showed that copper supplementation potentiates the activity of the azole antifungal fluconazole against the opportunistic fungal pathogen C. albicans. Here, we report eight new azole analogues derived from fluconazole in which one triazole group has been replaced with a metal-binding group, a strategy designed to enhance potentiation of azole antifungal activity by copper. The bioactivity of all eight compounds was tested and compared to that of fluconazole. Three of the analogues showed activity against C. albicans and two had lower levels of trailing growth. One compound, Flu-TSCZ, was found to impact the levels, speciation, and bioavailability of cellular metals.

Full Text

Duke Authors

Cited Authors

  • Hunsaker, EW; McAuliffe, KJ; Franz, KJ

Published Date

  • June 15, 2020

Published In

PubMed ID

  • 32542530

Pubmed Central ID

  • 32542530

Electronic International Standard Serial Number (EISSN)

  • 1432-1327

International Standard Serial Number (ISSN)

  • 0949-8257

Digital Object Identifier (DOI)

  • 10.1007/s00775-020-01796-x

Language

  • eng